Database→Tesamorelin

Tier 1Weight LossMetabolicHormonalPREMIUM

Tesamorelin

Tesamorelin (EGRIFTA / EGRIFTA SV / EGRIFTA WR) · Modified GHRH 1-44 · Trans-3-Hexenoic Acid GHRH

FDA-approved since November 2010 (EGRIFTA) for reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy. EGRIFTA WR (F8 once-weekly formulation) additionally approved March 2025. Biologics License Application. WADA: GHRH analogs prohibited at all times.

For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use

Profile Overview

Tesamorelin (EGRIFTA) is the only FDA-approved GHRH analogue, approved since 2010 for HIV-associated lipodystrophy, with a March 2025 approval of the once-weekly EGRIFTA WR formulation. Two Phase 3 RCTs (n=806) established 15 to 20% selective visceral fat reduction. NIH-funded off-label research shows compelling MASLD liver fat reduction (35% complete resolution at 12 months), cognitive function improvements, and skeletal muscle benefits.

🔒

Full Profile: Premium Members Only

The complete Tesamorelin profile includes all use cases with full evidence reviews, mechanism of action deep dive, safety analysis, evidence table, dosing guidance, and stack compatibility data.

For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use